Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.05. | BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors | 3 | Insider Monkey | ||
27.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.05. | bioAffinity Technologies names new chief medical officer | 2 | Investing.com | ||
20.05. | bioAffinity Technologies appoints Gordon Downie as chief medical officer | 2 | Seeking Alpha | ||
19.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
15.05. | bioAffinity Technologies GAAP EPS of -$0.16, revenue of $1.9M | 3 | Seeking Alpha | ||
08.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
07.05. | bioAffinity Technologies completes $3.25 million offering | 1 | Investing.com | ||
07.05. | bioAffinity Technologies schließt Kapitalerhöhung von 3,25 Millionen US-Dollar ab | 5 | Investing.com Deutsch | ||
06.05. | bioAffinity kündigt Wertpapierangebot von 3,25 Millionen US-Dollar an | 9 | Investing.com Deutsch | ||
06.05. | bioAffinity announces $3.25 million securities offering | - | Investing.com | ||
05.05. | bioAffinity Technologies, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
02.05. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
29.04. | bioAffinity Technologies, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
17.04. | bioAffinity Technologies optimiert Lungenkrebs-Erkennungstest | 2 | Investing.com Deutsch | ||
17.04. | bioAffinity Technologies streamlines lung cancer detection test | 1 | Investing.com | ||
17.04. | RedChip Companies, Inc.: ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 427 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / April 17, 2025 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks... ► Artikel lesen | |
14.04. | bioAffinity Technologies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
11.04. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,120 | -1,64 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,480 | +17,07 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 0,880 | -10,66 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
BURCON NUTRASCIENCE | 2,635 | +1,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,252 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1US15117F8077 Cellectar... ► Artikel lesen | |
IDORSIA | 2,165 | 0,00 % | Idorsia vor dem Showdown: Schicksalswochen für die Schweizer Biotech-Aktie - Börsenplatz Zürich | Finanzielle Schieflage, ein bevorstehender Führungswechsel und eine kritische Gläubigerversammlung machen den Schweizer Biotechwert derzeit zu einem echten Zitterkandidaten an der Börse. Am 25. Juni... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 7,700 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements | NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA... ► Artikel lesen | |
IMMUNIC | 0,602 | +1,01 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,096 | +1,49 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |